findmyKOL
Clinical trialNCT04042740CompletedPhase 2Interventional

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

SponsorAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsEnrollment45HIV InfectionHepatitis C Infection
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study was to assess the efficacy of a fixed dose combination (FDC) of glecaprevir/pibrentasvir (G/P) given for 4 weeks for treatment of acute hepatitis C (HCV), with or without HIV-1 coinfection.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil
  • Instituto de Pesquisa Clinica Evandro Chagas (12101)

    Rio de Janeiro, Brazil

United States
  • Ucsd, Avrc Crs (701)

    San Diego, California, United States

  • University of California, San Francisco Hiv/aids Crs (801)

    San Francisco, California, United States

  • University of Colorado Hospital Crs (6101)

    Aurora, Colorado, United States

  • Whitman-Walker Institute, Inc. Crs (31791)

    Washington D.C., District of Columbia, United States

  • Johns Hopkins Adult Aids Crs

    Baltimore, Maryland, United States

  • Massachusetts General Hospital Actg Crs (101)

    Boston, Massachusetts, United States

  • Columbia Physicians and Surgeons Crs (30329)

    New York, New York, United States

  • Weill Cornell Chelsea Crs (7804)

    New York, New York, United States

  • Weill Cornell Upton Crs (7803)

    New York, New York, United States

  • Unc Aids Crs (3201)

    Chapel Hill, North Carolina, United States

  • University of Washington Aids Crs (1401)

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Glecaprevir →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Nov 2019
Primary completion
18 May 2023
Completion
22 Aug 2023
Last update posted
11 Jul 2024
Registered enrollment
45
Registry id
NCT04042740
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.